ClinicalTrials.gg
CompletedNCT07542847Updated Jun 5, 2026Results posted

A Study to Test the Effects of Itraconazole and Carbamazepine on OPC-167832 in Healthy Men and Women

A Phase 1 interventional study of OPC-167832 and Itraconazole in Healthy Volunteers, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-05.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 3 years 6 months after the study started (first participant enrolled Sep 2022, registered Apr 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 129 studies in Tuberculosis with a site in United States — 4 open to participants now, 4 under way, none of them phase 3. Tuberculosis · United States.

Enrollment
69th of 94
24 · median 56
Started
2022
with 3 others
Phase 1
44 of 129
1 open now
Registered
127th of 129
by date

Among the 129 studies in Tuberculosis with a site in United States, this one is the 69th largest by enrollment of the 94 interventional ones that give a count, is one of 4 that started in 2022, is one of 44 in phase 1, and was the 127th registered.

Tuberculosis

1,170 studies on the registry are indexed under Tuberculosis; 175 are open to participants now.

Browse Tuberculosis studies →

Open to participants now

4 of the 129 studies in Tuberculosis with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 111 Tuberculosis studies recruiting now, 65 (59%) set no upper age limit and 36 (32%) stop at 75 or younger; 48 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 129 studies in Tuberculosis with a site in United States, or all of them as a file.
02

Study summary

The purpose of this trial is to assess the potential for cytochrome P450 (CYP)-mediated drug-drug interactions (DDIs) with OPC-167832. The study is conducted in 2 parts: Part 1 assesses the potential effect of the CYP3A inhibitor itraconazole on the metabolism of OPC-167832 and Part 2 assesses the potential effect of the CYP3A inducer carbamazepine on the metabolism of OPC-167832 in healthy adult participants.

03

Conditions studied

  • Healthy Volunteers

Browse trials for

Keywords

  • Tuberculosis
  • TB
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. (BMI) between 19.0 to 32.0 kilograms per square meter (kg/m\^2), inclusive.
  2. In good health at screening as determined by:

    1. Medical history
    2. Physical examination
    3. Serum/urine chemistry, hematology, and serology tests
  3. Ability to provide written, prior to initiation of any trial-related procedures, and ability, in the opinion of the principal investigator, to comply with all the requirements of the trial

Exclusion criteria

Exclusion Criteria

  1. abnormality in past medical history, or at the screening physical examination, that in the investigator's or sponsor's opinion may place the participants at risk or interfere with outcome variables including absorption, distribution, metabolism, and excretion of drug.
  2. History of drug and/or alcohol abuse (as defined by the , Fifth Edition criteria for moderate to severe alcohol/substance use disorder) within 2 years prior to the screening visit.
  3. History of or current hepatitis or acquired immunodeficiency syndrome or carriers of surface antigen, antibodies, and/or antibodies.
  4. History of any clinically significant drug allergy or known or suspected , to any component of the IMP including structurally related drugs (eg, tricyclic antidepressants), hereditary fructose intolerance (Part 1 only), or any of the .
  5. A positive urine alcohol test and/or urine drug screen for substances of abuse at the screening visit or upon check-in to the trial site.
  6. Participants having taken an drug within 30 days prior to the screening visit.
  7. Any history of clinically significant hemorrhagic tendencies.
  8. Having received a vaccine within 14 days prior to dosing
  9. Any participant who, in the opinion of the investigator, should not participate in the trial.
  10. Female participants who are breast-feeding or who have a positive pregnancy test result prior to receiving IMP.
  11. Participants without a permanent physical residence.
  12. History of suicide ideation or severe depression that, in the opinion of the investigator, would exclude the participant from participating in this trial (applicable to Part 2 only).

Note: Other protocol-specified inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Part 1: OPC-167832 and Itraconazole

    Participants receive single OPC-167832 dose, orally on Days 1 and 15, and itraconazole, orally, twice daily (BID), on Day 8 followed by itraconazole, once daily (QD) from Day 9 to Day 25 of Part 1.

    Drug: OPC-167832 · Drug: Itraconazole

  • Experimental
    Part 2: OPC-167832 and Carbamazepine

    Participants receive single OPC-167832 dose, orally on Days 1 and 25, and carbamazepine Dose 1, orally, BID from Day 8 to Day 10, followed by Dose 2, BID from Day 11 to Day 13, and Dose 3, BID from Day 14 to Day 31 of Part 2.

    Drug: OPC-167832 · Drug: Carbamazepine

Interventions

06

What researchers measure

Primary outcomes

  1. Part 1: Maximum Plasma Concentration (Cmax) of OPC-167832

    Time frame: Predose and up to 168 hours postdose on Day 1; and Predose and up to 264 hours postdose on Day 15.

  2. Part 2: Cmax of OPC-167832

    Time frame: Predose and up to 168 hours postdose on Day 1; and Predose and up to 168 hours postdose on Day 25.

  3. Part 1: Area Under the Concentration-time Curve Calculated to the Last Observable Concentration at Time t (AUCt) of OPC-167832

    Time frame: Predose and up to 168 hours postdose on Day 1; and Predose and up to 264 hours postdose on Day 15.

  4. Part 2: AUCt of OPC-167832

    Time frame: Predose and up to 168 hours postdose on Day 1; and Predose and up to 168 hours postdose on Day 25.

  5. Part 1: Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinfinity) of OPC-167832

    Time frame: Predose and up to 168 hours postdose on Day 1; and Predose and up to 264 hours postdose on Day 15.

  6. Part 2: AUCinfinity of OPC-167832

    Time frame: Predose and upto 168 hours postdose on Day 1; and Predose and upto 168 hours postdose on Day 25.

Secondary outcomes

  1. Parts 1 and 2: Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    An adverse event (AE) is defined as any untoward medical occurrence in a clinical trial participant administered a trial intervention and which does not necessarily have a causal relationship with this intervention. TEAEs are defined as AEs with an onset date on or after the start of IMP treatment.

    Time frame: Part 1: Up to 8 weeks; Part 2: Up to 9 weeks

  2. Parts 1 and 2: Number of Participants With Potentially Clinically Significant Changes in Clinical Laboratory Test Parameters

    Clinical laboratory tests for serum chemistry, hematology, and urinalysis were measured. Clinical significance was determined by the investigator.

    Time frame: Part 1: Up to 8 weeks; Part 2: Up to 9 weeks

  3. Parts 1 and 2: Number of Participants With Clinically Significant Changes in Vital Signs Abnormalities

    Vital signs criteria for clinically significant changes: systolic blood pressure (greater than \[\>\]160 millimeters of mercury \[mmHg\] to less than \[\<\]90 mmHg), diastolic blood pressure (\>105 mmHg to \<50 mmHg), heart rate (\>110 beats per minute \[bpm\] to \<50 bpm), respiratory rate (\<12 breaths/min or \> 20 breaths/min), and temperature (\<36 degree Celsius \[°C\] or \>38°C).

    Time frame: Part 1: Up to 8 weeks; Part 2: Up to 9 weeks

  4. Parts 1 and 2: Number of Participants With Potentially Clinically Significant Changes in Physical Examinations

    The physical examination included height (screening only), weight, and calculation of body mass index (BMI), as well as assessment of the head, neck, eyes, ears, nose, and throat; thorax; abdomen; skin and mucosae; neurological; and extremities. Clinical significance was determined by the investigator.

    Time frame: Part 1: Up to 8 weeks; Part 2: Up to 9 weeks

  5. Parts 1 and 2: Number of Participants With Potentially Clinically Relevant Changes in 12-lead Electrocardiogram (ECG) Parameters

    Electrocardiogram measurements included heart rate (HR), PR, QRS, RR, QT, QTcF, QTcB). The participants were assessed based on the clinically relevant changes in ECG values as per criteria defined in SAP.

    Time frame: Part 1: Up to 8 weeks; Part 2: Up to 9 weeks

  6. Part 2: Number of Participants With Changes in Columbia-Suicide Severity Rating Scale (C-SSRS)

    The C-SSRS was an interview-based rating scale to systematically assess suicidal ideation, suicidal behavior and non-suicidal self-injurious behavior. The C-SSRS includes 'yes' or 'no' responses for assessment of suicidal behavior (preparatory acts or behavior, aborted attempt, interrupted attempt, suicidal behavior, completed suicide), suicidal ideation (wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with any methods, active suicidal ideation with some intent, active suicidal ideation with specific plan and intent) and non-suicidal self-injurious behavior.

    Time frame: Up to 9 weeks

07

Results

Posted Jun 5, 2026

Participant flow

Participants took part in the study from 19 September 2022 to 11 December 2022.

Participant flow — Overall Study
MilestonePart 1: OPC-167832 and ItraconazolePart 2: OPC-167832 and Carbamazepine
Started1212
Completed99
Not completed33
Withdrew: Adverse event33

Outcome measures

PrimaryPart 1: Maximum Plasma Concentration (Cmax) of OPC-167832
Time frame:
Predose and up to 168 hours postdose on Day 1; and Predose and up to 264 hours postdose on Day 15.
Reported as:
Mean · nanograms per milliliter (ng/mL)
Part 1: Maximum Plasma Concentration (Cmax) of OPC-167832
nanograms per milliliter (ng/mL)OPC-167832OPC-167832 and Itraconazole
Part 1: Maximum Plasma Concentration (Cmax) of OPC-16783281.0 ± 29.3144 ± 66.7
Statistical analysis
  • OPC-167832 vs OPC-167832 and Itraconazole · Geometric mean ratio (gmr): 1.723 · 90% CI 1.410 to 2.106
PrimaryPart 2: Cmax of OPC-167832
Time frame:
Predose and up to 168 hours postdose on Day 1; and Predose and up to 168 hours postdose on Day 25.
Reported as:
Mean · ng/mL
Part 2: Cmax of OPC-167832
ng/mLOPC-167832OPC-167832 and Carbamazepine
Part 2: Cmax of OPC-16783295.1 ± 36.695.8 ± 32.9
Statistical analysis
  • OPC-167832 vs OPC-167832 and Carbamazepine · Gmr: 1.07 · 90% CI 0.926 to 1.236
PrimaryPart 1: Area Under the Concentration-time Curve Calculated to the Last Observable Concentration at Time t (AUCt) of OPC-167832
Time frame:
Predose and up to 168 hours postdose on Day 1; and Predose and up to 264 hours postdose on Day 15.
Reported as:
Mean · Nanograms*hours per milliliter (ng*h/mL)
Part 1: Area Under the Concentration-time Curve Calculated to the Last Observable Concentration at Time t (AUCt) of OPC-167832
Nanograms*hours per milliliter (ng*h/mL)OPC-167832OPC-167832 and Itraconazole
Part 1: Area Under the Concentration-time Curve Calculated to the Last Observable Concentration at Time t (AUCt) of OPC-1678322310 ± 8984490 ± 2390
Statistical analysis
  • OPC-167832 vs OPC-167832 and Itraconazole · Gmr: 1.82 · 90% CI 1.568 to 2.113
PrimaryPart 2: AUCt of OPC-167832
Time frame:
Predose and up to 168 hours postdose on Day 1; and Predose and up to 168 hours postdose on Day 25.
Reported as:
Mean · ng*h/mL
Part 2: AUCt of OPC-167832
ng*h/mLOPC-167832OPC-167832 and Carbamazepine
Part 2: AUCt of OPC-1678322280 ± 8081310 ± 345
Statistical analysis
  • OPC-167832 vs OPC-167832 and Carbamazepine · Gmr: 0.599 · 90% CI 0.505 to 0.711
PrimaryPart 1: Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinfinity) of OPC-167832
Time frame:
Predose and up to 168 hours postdose on Day 1; and Predose and up to 264 hours postdose on Day 15.
Reported as:
Mean · ng*h/mL
Part 1: Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinfinity) of OPC-167832
ng*h/mLOPC-167832OPC-167832 and Itraconazole
Part 1: Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinfinity) of OPC-1678322180 ± 6193660 ± 1170
Statistical analysis
  • OPC-167832 vs OPC-167832 and Itraconazole · Gmr: 1.75 · 90% CI 1.481 to 2.068
PrimaryPart 2: AUCinfinity of OPC-167832
Time frame:
Predose and upto 168 hours postdose on Day 1; and Predose and upto 168 hours postdose on Day 25.
Reported as:
Mean · ng*h/mL
Part 2: AUCinfinity of OPC-167832
ng*h/mLOPC-167832OPC-167832 and Carbamazepine
Part 2: AUCinfinity of OPC-1678322330 ± 8681350 ± 234
Statistical analysis
  • OPC-167832 vs OPC-167832 and Carbamazepine · Gmr: 0.642 · 90% CI 0.499 to 0.826
SecondaryParts 1 and 2: Number of Participants With Treatment-emergent Adverse Events (TEAEs)

An adverse event (AE) is defined as any untoward medical occurrence in a clinical trial participant administered a trial intervention and which does not necessarily have a causal relationship with this intervention. TEAEs are defined as AEs with an onset date on or after the start of IMP treatment.

Time frame:
Part 1: Up to 8 weeks; Part 2: Up to 9 weeks
Reported as:
Count of participants · Participants
Parts 1 and 2: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsPart 1: OPC-167832 and ItraconazolePart 2: OPC-167832 and Carbamazepine
Parts 1 and 2: Number of Participants With Treatment-emergent Adverse Events (TEAEs)710
SecondaryParts 1 and 2: Number of Participants With Potentially Clinically Significant Changes in Clinical Laboratory Test Parameters

Clinical laboratory tests for serum chemistry, hematology, and urinalysis were measured. Clinical significance was determined by the investigator.

Time frame:
Part 1: Up to 8 weeks; Part 2: Up to 9 weeks
Reported as:
Count of participants · Participants
Parts 1 and 2: Number of Participants With Potentially Clinically Significant Changes in Clinical Laboratory Test Parameters
ParticipantsPart 1: OPC-167832 and ItraconazolePart 2: OPC-167832 and Carbamazepine
Parts 1 and 2: Number of Participants With Potentially Clinically Significant Changes in Clinical Laboratory Test Parameters00
SecondaryParts 1 and 2: Number of Participants With Clinically Significant Changes in Vital Signs Abnormalities

Vital signs criteria for clinically significant changes: systolic blood pressure (greater than \[\>\]160 millimeters of mercury \[mmHg\] to less than \[\<\]90 mmHg), diastolic blood pressure (\>105 mmHg to \<50 mmHg), heart rate (\>110 beats per minute \[bpm\] to \<50 bpm), respiratory rate (\<12 breaths/min or \> 20 breaths/min), and temperature (\<36 degree Celsius \[°C\] or \>38°C).

Time frame:
Part 1: Up to 8 weeks; Part 2: Up to 9 weeks
Reported as:
Count of participants · Participants
Parts 1 and 2: Number of Participants With Clinically Significant Changes in Vital Signs Abnormalities
ParticipantsPart 1: OPC-167832 and ItraconazolePart 2: OPC-167832 and Carbamazepine
Parts 1 and 2: Number of Participants With Clinically Significant Changes in Vital Signs Abnormalities00
SecondaryParts 1 and 2: Number of Participants With Potentially Clinically Significant Changes in Physical Examinations

The physical examination included height (screening only), weight, and calculation of body mass index (BMI), as well as assessment of the head, neck, eyes, ears, nose, and throat; thorax; abdomen; skin and mucosae; neurological; and extremities. Clinical significance was determined by the investigator.

Time frame:
Part 1: Up to 8 weeks; Part 2: Up to 9 weeks
Reported as:
Count of participants · Participants
Parts 1 and 2: Number of Participants With Potentially Clinically Significant Changes in Physical Examinations
ParticipantsPart 1: OPC-167832 and ItraconazolePart 2: OPC-167832 and Carbamazepine
Parts 1 and 2: Number of Participants With Potentially Clinically Significant Changes in Physical Examinations00
SecondaryParts 1 and 2: Number of Participants With Potentially Clinically Relevant Changes in 12-lead Electrocardiogram (ECG) Parameters

Electrocardiogram measurements included heart rate (HR), PR, QRS, RR, QT, QTcF, QTcB). The participants were assessed based on the clinically relevant changes in ECG values as per criteria defined in SAP.

Time frame:
Part 1: Up to 8 weeks; Part 2: Up to 9 weeks
Reported as:
Count of participants · Participants
Parts 1 and 2: Number of Participants With Potentially Clinically Relevant Changes in 12-lead Electrocardiogram (ECG) Parameters
ParticipantsPart 1: OPC-167832 and ItraconazolePart 2: OPC-167832 and Carbamazepine
Parts 1 and 2: Number of Participants With Potentially Clinically Relevant Changes in 12-lead Electrocardiogram (ECG) Parameters00
SecondaryPart 2: Number of Participants With Changes in Columbia-Suicide Severity Rating Scale (C-SSRS)

The C-SSRS was an interview-based rating scale to systematically assess suicidal ideation, suicidal behavior and non-suicidal self-injurious behavior. The C-SSRS includes 'yes' or 'no' responses for assessment of suicidal behavior (preparatory acts or behavior, aborted attempt, interrupted attempt, suicidal behavior, completed suicide), suicidal ideation (wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with any methods, active suicidal ideation with some intent, active suicidal ideation with specific plan and intent) and non-suicidal self-injurious behavior.

Time frame:
Up to 9 weeks
Reported as:
Count of participants · Participants
Part 2: Number of Participants With Changes in Columbia-Suicide Severity Rating Scale (C-SSRS)
ParticipantsPart 2: OPC-167832 and Carbamazepine
Suicidal Behavior0
Suicidal Ideation0

Adverse events

Collected over Part 1: Up to 8 weeks; Part 2: Up to 9 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: OPC-167832 and Itraconazole0/12 (0%)0/12 (0%)7/12 (58.3%)
Part 2: OPC-167832 and Carbamazepine0/12 (0%)0/12 (0%)10/12 (83.3%)
Most frequent other events
Showing 10 of 35
Most frequent other events
EventPart 1: OPC-167832 and ItraconazolePart 2: OPC-167832 and Carbamazepine
DiarrhoeaGastrointestinal disorders5/121/12
NauseaGastrointestinal disorders2/125/12
HeadacheNervous system disorders3/125/12
Vision BlurredEye disorders4/122/12
DizzinessNervous system disorders3/123/12
Abdominal PainGastrointestinal disorders2/121/12
LymphadenopathyBlood and lymphatic system disorders0/122/12
Non-cardiac Chest PainGeneral disorders0/122/12
Disturbance in AttentionNervous system disorders0/122/12
SomnolenceNervous system disorders0/122/12

Baseline characteristics

The enrolled analysis dataset includes all participants that signed the informed consent form (ICF) and met all eligibility criteria.

Age, Continuous
Age, Continuous(years)Part 1: OPC-167832 and ItraconazolePart 2: OPC-167832 and CarbamazepineTotal
Mean37.5 ± 11.139.8 ± 9.338.6 ± 10.1
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: OPC-167832 and ItraconazolePart 2: OPC-167832 and CarbamazepineTotal
Female549
Male7815
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1: OPC-167832 and ItraconazolePart 2: OPC-167832 and CarbamazepineTotal
Hispanic or Latino033
Not Hispanic or Latino12921
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part 1: OPC-167832 and ItraconazolePart 2: OPC-167832 and CarbamazepineTotal
White4711
Black or African American7411
Asian101
Other011
08

Study locations

1 site
  • ICON plc
    Lenexa, Kansas 66219, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Anonymized individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2022 to primary completion in Nov 2022, 1 month.

Results were first posted in Jun 2026, 3 years 6 months after primary completion.

Of 60 phase 1 interventional studies under Tuberculosis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 25. This study's 1 month is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2026
First posted
Apr 21, 2026
StartActual
Sep 19, 2022
Primary completionActual
Nov 18, 2022
CompletionActual
Dec 11, 2022
Results first posted
Jun 5, 2026
Last update
Jun 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07542847
Responsible party
Sponsor
First posted
Apr 21, 2026
Start date
Sep 19, 2022
Primary completion
Nov 18, 2022
Completion
Dec 11, 2022
Results posted
Jun 5, 2026
Last update
Jun 5, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Quabodepistat

Start the discussion